Global Mesalamine Market

Mesalamine Comprehensive Study by Type (Capsule, Tablets, Rectal Enema), Application (Hospital, Pharmacies, Medical Stores), Mode of Administration (Oral, Rectal), Dosage (250 mg, 375 mg, 400 mg, 500 mg, 800 mg), End User (Adult, Children) Players and Region - Global Market Outlook to 2026

Mesalamine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Mesalamine Market Scope?
Mesalamine is used to treat ulcerative colitis, also to maintain the improvement of ulcerative colitis symptoms and mild to moderate Crohn's disease. Mesalamine is in a class of medications called anti-inflammatory agents. Mesalamine is available under different brand names such as Asacol HD, Pentasa, Delzicol, Lialda, and Apriso. Rising prevalence of inflammatory bowel disease such as ulcerative colitis boosting the demand for mesalamine.

The Mesalamine market study is being classified by Type (Capsule, Tablets and Rectal Enema), by Application (Hospital, Pharmacies and Medical Stores) and major geographies with country level break-up.

Analysts at AMA predicts that Players from Global will contribute to the maximum growth of Global Mesalamine market throughout the predicted period.

Salix Pharmaceuticals, Inc. (United States), Nogra Pharma Limited (Ireland), AstraZeneca plc (United Kingdom), AbbVie (United States), The Takeda Pharmaceutical (Japan), Janssen Pharmaceutica (Belgium), Pfizer Inc. (United States), Ferring Holding SA (Switzerland), C.H. Boehringer Sohn AG & Ko. (Germany) and Cosmo Pharmaceuticals (Ireland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Teva Pharmaceutical Industries Ltd.(Israel) and Mylan N.V. (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Mesalamine market by Type, Application and Region.

On the basis of geography, the market of Mesalamine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their development strategies

In Mar 2018, Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Lialda®1 (mesalamine) delayed-release tablets, 1.2 g, in the U.S.


Influencing Market Trend
  • Rising Number of Clinical Trials

Market Drivers
  • Increasing Prevalence of Inflammatory Bowel Disease such as Ulcerative Colitis
  • Increasing Healthcare Expenditure in Developing Countries

Opportunities
  • Rising Reasecha and Development Activities in Emerging Countries
  • Growth in the Pharmaceutical Industry

Restraints
  • Stringent Government Regulations for Approval

Challenges
  • Mesalamine may cause Some side effects such as Muscle or Joint Pain, Aching, Nausea and etc.


Key Target Audience
Mesalamine Manufacturers, Raw Material Suppliers, Healthcare Industry, Pharmaceutical Industry and Potential Investors

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Capsule
  • Tablets
  • Rectal Enema
By Application
  • Hospital
  • Pharmacies
  • Medical Stores
By Mode of Administration
  • Oral
  • Rectal

By Dosage
  • 250 mg
  • 375 mg
  • 400 mg
  • 500 mg
  • 800 mg

By End User
  • Adult
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Inflammatory Bowel Disease such as Ulcerative Colitis
      • 3.2.2. Increasing Healthcare Expenditure in Developing Countries
    • 3.3. Market Challenges
      • 3.3.1. Mesalamine may cause Some side effects such as Muscle or Joint Pain, Aching, Nausea and etc.
    • 3.4. Market Trends
      • 3.4.1. Rising Number of Clinical Trials
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mesalamine, by Type, Application, Mode of Administration, Dosage, End User and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Mesalamine (Value)
      • 5.2.1. Global Mesalamine by: Type (Value)
        • 5.2.1.1. Capsule
        • 5.2.1.2. Tablets
        • 5.2.1.3. Rectal Enema
      • 5.2.2. Global Mesalamine by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Pharmacies
        • 5.2.2.3. Medical Stores
      • 5.2.3. Global Mesalamine by: Mode of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Rectal
      • 5.2.4. Global Mesalamine by: Dosage (Value)
        • 5.2.4.1. 250 mg
        • 5.2.4.2. 375 mg
        • 5.2.4.3. 400 mg
        • 5.2.4.4. 500 mg
        • 5.2.4.5. 800 mg
      • 5.2.5. Global Mesalamine by: End User (Value)
        • 5.2.5.1. Adult
        • 5.2.5.2. Children
      • 5.2.6. Global Mesalamine Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Mesalamine (Volume)
      • 5.3.1. Global Mesalamine by: Type (Volume)
        • 5.3.1.1. Capsule
        • 5.3.1.2. Tablets
        • 5.3.1.3. Rectal Enema
      • 5.3.2. Global Mesalamine by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Pharmacies
        • 5.3.2.3. Medical Stores
      • 5.3.3. Global Mesalamine by: Mode of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Rectal
      • 5.3.4. Global Mesalamine by: Dosage (Volume)
        • 5.3.4.1. 250 mg
        • 5.3.4.2. 375 mg
        • 5.3.4.3. 400 mg
        • 5.3.4.4. 500 mg
        • 5.3.4.5. 800 mg
      • 5.3.5. Global Mesalamine by: End User (Volume)
        • 5.3.5.1. Adult
        • 5.3.5.2. Children
      • 5.3.6. Global Mesalamine Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Mesalamine (Price)
      • 5.4.1. Global Mesalamine by: Type (Price)
  • 6. Mesalamine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Salix Pharmaceuticals, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Nogra Pharma Limited (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AbbVie (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. The Takeda Pharmaceutical (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Janssen Pharmaceutica (Belgium)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ferring Holding SA (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. C.H. Boehringer Sohn AG & Ko. (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Cosmo Pharmaceuticals (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Mesalamine Sale, by Type, Application, Mode of Administration, Dosage, End User and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Mesalamine (Value)
      • 7.2.1. Global Mesalamine by: Type (Value)
        • 7.2.1.1. Capsule
        • 7.2.1.2. Tablets
        • 7.2.1.3. Rectal Enema
      • 7.2.2. Global Mesalamine by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Pharmacies
        • 7.2.2.3. Medical Stores
      • 7.2.3. Global Mesalamine by: Mode of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Rectal
      • 7.2.4. Global Mesalamine by: Dosage (Value)
        • 7.2.4.1. 250 mg
        • 7.2.4.2. 375 mg
        • 7.2.4.3. 400 mg
        • 7.2.4.4. 500 mg
        • 7.2.4.5. 800 mg
      • 7.2.5. Global Mesalamine by: End User (Value)
        • 7.2.5.1. Adult
        • 7.2.5.2. Children
      • 7.2.6. Global Mesalamine Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Mesalamine (Volume)
      • 7.3.1. Global Mesalamine by: Type (Volume)
        • 7.3.1.1. Capsule
        • 7.3.1.2. Tablets
        • 7.3.1.3. Rectal Enema
      • 7.3.2. Global Mesalamine by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Pharmacies
        • 7.3.2.3. Medical Stores
      • 7.3.3. Global Mesalamine by: Mode of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Rectal
      • 7.3.4. Global Mesalamine by: Dosage (Volume)
        • 7.3.4.1. 250 mg
        • 7.3.4.2. 375 mg
        • 7.3.4.3. 400 mg
        • 7.3.4.4. 500 mg
        • 7.3.4.5. 800 mg
      • 7.3.5. Global Mesalamine by: End User (Volume)
        • 7.3.5.1. Adult
        • 7.3.5.2. Children
      • 7.3.6. Global Mesalamine Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Mesalamine (Price)
      • 7.4.1. Global Mesalamine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mesalamine: by Type(USD Million)
  • Table 2. Mesalamine Capsule , by Region USD Million (2015-2020)
  • Table 3. Mesalamine Tablets , by Region USD Million (2015-2020)
  • Table 4. Mesalamine Rectal Enema , by Region USD Million (2015-2020)
  • Table 5. Mesalamine: by Application(USD Million)
  • Table 6. Mesalamine Hospital , by Region USD Million (2015-2020)
  • Table 7. Mesalamine Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Mesalamine Medical Stores , by Region USD Million (2015-2020)
  • Table 9. Mesalamine: by Mode of Administration(USD Million)
  • Table 10. Mesalamine Oral , by Region USD Million (2015-2020)
  • Table 11. Mesalamine Rectal , by Region USD Million (2015-2020)
  • Table 12. Mesalamine: by Dosage(USD Million)
  • Table 13. Mesalamine 250 mg , by Region USD Million (2015-2020)
  • Table 14. Mesalamine 375 mg , by Region USD Million (2015-2020)
  • Table 15. Mesalamine 400 mg , by Region USD Million (2015-2020)
  • Table 16. Mesalamine 500 mg , by Region USD Million (2015-2020)
  • Table 17. Mesalamine 800 mg , by Region USD Million (2015-2020)
  • Table 18. Mesalamine: by End User(USD Million)
  • Table 19. Mesalamine Adult , by Region USD Million (2015-2020)
  • Table 20. Mesalamine Children , by Region USD Million (2015-2020)
  • Table 21. South America Mesalamine, by Country USD Million (2015-2020)
  • Table 22. South America Mesalamine, by Type USD Million (2015-2020)
  • Table 23. South America Mesalamine, by Application USD Million (2015-2020)
  • Table 24. South America Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 25. South America Mesalamine, by Dosage USD Million (2015-2020)
  • Table 26. South America Mesalamine, by End User USD Million (2015-2020)
  • Table 27. Brazil Mesalamine, by Type USD Million (2015-2020)
  • Table 28. Brazil Mesalamine, by Application USD Million (2015-2020)
  • Table 29. Brazil Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 30. Brazil Mesalamine, by Dosage USD Million (2015-2020)
  • Table 31. Brazil Mesalamine, by End User USD Million (2015-2020)
  • Table 32. Argentina Mesalamine, by Type USD Million (2015-2020)
  • Table 33. Argentina Mesalamine, by Application USD Million (2015-2020)
  • Table 34. Argentina Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 35. Argentina Mesalamine, by Dosage USD Million (2015-2020)
  • Table 36. Argentina Mesalamine, by End User USD Million (2015-2020)
  • Table 37. Rest of South America Mesalamine, by Type USD Million (2015-2020)
  • Table 38. Rest of South America Mesalamine, by Application USD Million (2015-2020)
  • Table 39. Rest of South America Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 40. Rest of South America Mesalamine, by Dosage USD Million (2015-2020)
  • Table 41. Rest of South America Mesalamine, by End User USD Million (2015-2020)
  • Table 42. Asia Pacific Mesalamine, by Country USD Million (2015-2020)
  • Table 43. Asia Pacific Mesalamine, by Type USD Million (2015-2020)
  • Table 44. Asia Pacific Mesalamine, by Application USD Million (2015-2020)
  • Table 45. Asia Pacific Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 46. Asia Pacific Mesalamine, by Dosage USD Million (2015-2020)
  • Table 47. Asia Pacific Mesalamine, by End User USD Million (2015-2020)
  • Table 48. China Mesalamine, by Type USD Million (2015-2020)
  • Table 49. China Mesalamine, by Application USD Million (2015-2020)
  • Table 50. China Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 51. China Mesalamine, by Dosage USD Million (2015-2020)
  • Table 52. China Mesalamine, by End User USD Million (2015-2020)
  • Table 53. Japan Mesalamine, by Type USD Million (2015-2020)
  • Table 54. Japan Mesalamine, by Application USD Million (2015-2020)
  • Table 55. Japan Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 56. Japan Mesalamine, by Dosage USD Million (2015-2020)
  • Table 57. Japan Mesalamine, by End User USD Million (2015-2020)
  • Table 58. India Mesalamine, by Type USD Million (2015-2020)
  • Table 59. India Mesalamine, by Application USD Million (2015-2020)
  • Table 60. India Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 61. India Mesalamine, by Dosage USD Million (2015-2020)
  • Table 62. India Mesalamine, by End User USD Million (2015-2020)
  • Table 63. South Korea Mesalamine, by Type USD Million (2015-2020)
  • Table 64. South Korea Mesalamine, by Application USD Million (2015-2020)
  • Table 65. South Korea Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 66. South Korea Mesalamine, by Dosage USD Million (2015-2020)
  • Table 67. South Korea Mesalamine, by End User USD Million (2015-2020)
  • Table 68. Taiwan Mesalamine, by Type USD Million (2015-2020)
  • Table 69. Taiwan Mesalamine, by Application USD Million (2015-2020)
  • Table 70. Taiwan Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 71. Taiwan Mesalamine, by Dosage USD Million (2015-2020)
  • Table 72. Taiwan Mesalamine, by End User USD Million (2015-2020)
  • Table 73. Australia Mesalamine, by Type USD Million (2015-2020)
  • Table 74. Australia Mesalamine, by Application USD Million (2015-2020)
  • Table 75. Australia Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 76. Australia Mesalamine, by Dosage USD Million (2015-2020)
  • Table 77. Australia Mesalamine, by End User USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Mesalamine, by Type USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Mesalamine, by Application USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Mesalamine, by Dosage USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Mesalamine, by End User USD Million (2015-2020)
  • Table 83. Europe Mesalamine, by Country USD Million (2015-2020)
  • Table 84. Europe Mesalamine, by Type USD Million (2015-2020)
  • Table 85. Europe Mesalamine, by Application USD Million (2015-2020)
  • Table 86. Europe Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 87. Europe Mesalamine, by Dosage USD Million (2015-2020)
  • Table 88. Europe Mesalamine, by End User USD Million (2015-2020)
  • Table 89. Germany Mesalamine, by Type USD Million (2015-2020)
  • Table 90. Germany Mesalamine, by Application USD Million (2015-2020)
  • Table 91. Germany Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 92. Germany Mesalamine, by Dosage USD Million (2015-2020)
  • Table 93. Germany Mesalamine, by End User USD Million (2015-2020)
  • Table 94. France Mesalamine, by Type USD Million (2015-2020)
  • Table 95. France Mesalamine, by Application USD Million (2015-2020)
  • Table 96. France Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 97. France Mesalamine, by Dosage USD Million (2015-2020)
  • Table 98. France Mesalamine, by End User USD Million (2015-2020)
  • Table 99. Italy Mesalamine, by Type USD Million (2015-2020)
  • Table 100. Italy Mesalamine, by Application USD Million (2015-2020)
  • Table 101. Italy Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 102. Italy Mesalamine, by Dosage USD Million (2015-2020)
  • Table 103. Italy Mesalamine, by End User USD Million (2015-2020)
  • Table 104. United Kingdom Mesalamine, by Type USD Million (2015-2020)
  • Table 105. United Kingdom Mesalamine, by Application USD Million (2015-2020)
  • Table 106. United Kingdom Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 107. United Kingdom Mesalamine, by Dosage USD Million (2015-2020)
  • Table 108. United Kingdom Mesalamine, by End User USD Million (2015-2020)
  • Table 109. Netherlands Mesalamine, by Type USD Million (2015-2020)
  • Table 110. Netherlands Mesalamine, by Application USD Million (2015-2020)
  • Table 111. Netherlands Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 112. Netherlands Mesalamine, by Dosage USD Million (2015-2020)
  • Table 113. Netherlands Mesalamine, by End User USD Million (2015-2020)
  • Table 114. Rest of Europe Mesalamine, by Type USD Million (2015-2020)
  • Table 115. Rest of Europe Mesalamine, by Application USD Million (2015-2020)
  • Table 116. Rest of Europe Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 117. Rest of Europe Mesalamine, by Dosage USD Million (2015-2020)
  • Table 118. Rest of Europe Mesalamine, by End User USD Million (2015-2020)
  • Table 119. MEA Mesalamine, by Country USD Million (2015-2020)
  • Table 120. MEA Mesalamine, by Type USD Million (2015-2020)
  • Table 121. MEA Mesalamine, by Application USD Million (2015-2020)
  • Table 122. MEA Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 123. MEA Mesalamine, by Dosage USD Million (2015-2020)
  • Table 124. MEA Mesalamine, by End User USD Million (2015-2020)
  • Table 125. Middle East Mesalamine, by Type USD Million (2015-2020)
  • Table 126. Middle East Mesalamine, by Application USD Million (2015-2020)
  • Table 127. Middle East Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 128. Middle East Mesalamine, by Dosage USD Million (2015-2020)
  • Table 129. Middle East Mesalamine, by End User USD Million (2015-2020)
  • Table 130. Africa Mesalamine, by Type USD Million (2015-2020)
  • Table 131. Africa Mesalamine, by Application USD Million (2015-2020)
  • Table 132. Africa Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 133. Africa Mesalamine, by Dosage USD Million (2015-2020)
  • Table 134. Africa Mesalamine, by End User USD Million (2015-2020)
  • Table 135. North America Mesalamine, by Country USD Million (2015-2020)
  • Table 136. North America Mesalamine, by Type USD Million (2015-2020)
  • Table 137. North America Mesalamine, by Application USD Million (2015-2020)
  • Table 138. North America Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 139. North America Mesalamine, by Dosage USD Million (2015-2020)
  • Table 140. North America Mesalamine, by End User USD Million (2015-2020)
  • Table 141. United States Mesalamine, by Type USD Million (2015-2020)
  • Table 142. United States Mesalamine, by Application USD Million (2015-2020)
  • Table 143. United States Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 144. United States Mesalamine, by Dosage USD Million (2015-2020)
  • Table 145. United States Mesalamine, by End User USD Million (2015-2020)
  • Table 146. Canada Mesalamine, by Type USD Million (2015-2020)
  • Table 147. Canada Mesalamine, by Application USD Million (2015-2020)
  • Table 148. Canada Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 149. Canada Mesalamine, by Dosage USD Million (2015-2020)
  • Table 150. Canada Mesalamine, by End User USD Million (2015-2020)
  • Table 151. Mexico Mesalamine, by Type USD Million (2015-2020)
  • Table 152. Mexico Mesalamine, by Application USD Million (2015-2020)
  • Table 153. Mexico Mesalamine, by Mode of Administration USD Million (2015-2020)
  • Table 154. Mexico Mesalamine, by Dosage USD Million (2015-2020)
  • Table 155. Mexico Mesalamine, by End User USD Million (2015-2020)
  • Table 156. Mesalamine Sales: by Type(K Units)
  • Table 157. Mesalamine Sales Capsule , by Region K Units (2015-2020)
  • Table 158. Mesalamine Sales Tablets , by Region K Units (2015-2020)
  • Table 159. Mesalamine Sales Rectal Enema , by Region K Units (2015-2020)
  • Table 160. Mesalamine Sales: by Application(K Units)
  • Table 161. Mesalamine Sales Hospital , by Region K Units (2015-2020)
  • Table 162. Mesalamine Sales Pharmacies , by Region K Units (2015-2020)
  • Table 163. Mesalamine Sales Medical Stores , by Region K Units (2015-2020)
  • Table 164. Mesalamine Sales: by Mode of Administration(K Units)
  • Table 165. Mesalamine Sales Oral , by Region K Units (2015-2020)
  • Table 166. Mesalamine Sales Rectal , by Region K Units (2015-2020)
  • Table 167. Mesalamine Sales: by Dosage(K Units)
  • Table 168. Mesalamine Sales 250 mg , by Region K Units (2015-2020)
  • Table 169. Mesalamine Sales 375 mg , by Region K Units (2015-2020)
  • Table 170. Mesalamine Sales 400 mg , by Region K Units (2015-2020)
  • Table 171. Mesalamine Sales 500 mg , by Region K Units (2015-2020)
  • Table 172. Mesalamine Sales 800 mg , by Region K Units (2015-2020)
  • Table 173. Mesalamine Sales: by End User(K Units)
  • Table 174. Mesalamine Sales Adult , by Region K Units (2015-2020)
  • Table 175. Mesalamine Sales Children , by Region K Units (2015-2020)
  • Table 176. South America Mesalamine Sales, by Country K Units (2015-2020)
  • Table 177. South America Mesalamine Sales, by Type K Units (2015-2020)
  • Table 178. South America Mesalamine Sales, by Application K Units (2015-2020)
  • Table 179. South America Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 180. South America Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 181. South America Mesalamine Sales, by End User K Units (2015-2020)
  • Table 182. Brazil Mesalamine Sales, by Type K Units (2015-2020)
  • Table 183. Brazil Mesalamine Sales, by Application K Units (2015-2020)
  • Table 184. Brazil Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 185. Brazil Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 186. Brazil Mesalamine Sales, by End User K Units (2015-2020)
  • Table 187. Argentina Mesalamine Sales, by Type K Units (2015-2020)
  • Table 188. Argentina Mesalamine Sales, by Application K Units (2015-2020)
  • Table 189. Argentina Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 190. Argentina Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 191. Argentina Mesalamine Sales, by End User K Units (2015-2020)
  • Table 192. Rest of South America Mesalamine Sales, by Type K Units (2015-2020)
  • Table 193. Rest of South America Mesalamine Sales, by Application K Units (2015-2020)
  • Table 194. Rest of South America Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 195. Rest of South America Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 196. Rest of South America Mesalamine Sales, by End User K Units (2015-2020)
  • Table 197. Asia Pacific Mesalamine Sales, by Country K Units (2015-2020)
  • Table 198. Asia Pacific Mesalamine Sales, by Type K Units (2015-2020)
  • Table 199. Asia Pacific Mesalamine Sales, by Application K Units (2015-2020)
  • Table 200. Asia Pacific Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 201. Asia Pacific Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 202. Asia Pacific Mesalamine Sales, by End User K Units (2015-2020)
  • Table 203. China Mesalamine Sales, by Type K Units (2015-2020)
  • Table 204. China Mesalamine Sales, by Application K Units (2015-2020)
  • Table 205. China Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 206. China Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 207. China Mesalamine Sales, by End User K Units (2015-2020)
  • Table 208. Japan Mesalamine Sales, by Type K Units (2015-2020)
  • Table 209. Japan Mesalamine Sales, by Application K Units (2015-2020)
  • Table 210. Japan Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 211. Japan Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 212. Japan Mesalamine Sales, by End User K Units (2015-2020)
  • Table 213. India Mesalamine Sales, by Type K Units (2015-2020)
  • Table 214. India Mesalamine Sales, by Application K Units (2015-2020)
  • Table 215. India Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 216. India Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 217. India Mesalamine Sales, by End User K Units (2015-2020)
  • Table 218. South Korea Mesalamine Sales, by Type K Units (2015-2020)
  • Table 219. South Korea Mesalamine Sales, by Application K Units (2015-2020)
  • Table 220. South Korea Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 221. South Korea Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 222. South Korea Mesalamine Sales, by End User K Units (2015-2020)
  • Table 223. Taiwan Mesalamine Sales, by Type K Units (2015-2020)
  • Table 224. Taiwan Mesalamine Sales, by Application K Units (2015-2020)
  • Table 225. Taiwan Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 226. Taiwan Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 227. Taiwan Mesalamine Sales, by End User K Units (2015-2020)
  • Table 228. Australia Mesalamine Sales, by Type K Units (2015-2020)
  • Table 229. Australia Mesalamine Sales, by Application K Units (2015-2020)
  • Table 230. Australia Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 231. Australia Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 232. Australia Mesalamine Sales, by End User K Units (2015-2020)
  • Table 233. Rest of Asia-Pacific Mesalamine Sales, by Type K Units (2015-2020)
  • Table 234. Rest of Asia-Pacific Mesalamine Sales, by Application K Units (2015-2020)
  • Table 235. Rest of Asia-Pacific Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 236. Rest of Asia-Pacific Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 237. Rest of Asia-Pacific Mesalamine Sales, by End User K Units (2015-2020)
  • Table 238. Europe Mesalamine Sales, by Country K Units (2015-2020)
  • Table 239. Europe Mesalamine Sales, by Type K Units (2015-2020)
  • Table 240. Europe Mesalamine Sales, by Application K Units (2015-2020)
  • Table 241. Europe Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 242. Europe Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 243. Europe Mesalamine Sales, by End User K Units (2015-2020)
  • Table 244. Germany Mesalamine Sales, by Type K Units (2015-2020)
  • Table 245. Germany Mesalamine Sales, by Application K Units (2015-2020)
  • Table 246. Germany Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 247. Germany Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 248. Germany Mesalamine Sales, by End User K Units (2015-2020)
  • Table 249. France Mesalamine Sales, by Type K Units (2015-2020)
  • Table 250. France Mesalamine Sales, by Application K Units (2015-2020)
  • Table 251. France Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 252. France Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 253. France Mesalamine Sales, by End User K Units (2015-2020)
  • Table 254. Italy Mesalamine Sales, by Type K Units (2015-2020)
  • Table 255. Italy Mesalamine Sales, by Application K Units (2015-2020)
  • Table 256. Italy Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 257. Italy Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 258. Italy Mesalamine Sales, by End User K Units (2015-2020)
  • Table 259. United Kingdom Mesalamine Sales, by Type K Units (2015-2020)
  • Table 260. United Kingdom Mesalamine Sales, by Application K Units (2015-2020)
  • Table 261. United Kingdom Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 262. United Kingdom Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 263. United Kingdom Mesalamine Sales, by End User K Units (2015-2020)
  • Table 264. Netherlands Mesalamine Sales, by Type K Units (2015-2020)
  • Table 265. Netherlands Mesalamine Sales, by Application K Units (2015-2020)
  • Table 266. Netherlands Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 267. Netherlands Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 268. Netherlands Mesalamine Sales, by End User K Units (2015-2020)
  • Table 269. Rest of Europe Mesalamine Sales, by Type K Units (2015-2020)
  • Table 270. Rest of Europe Mesalamine Sales, by Application K Units (2015-2020)
  • Table 271. Rest of Europe Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 272. Rest of Europe Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 273. Rest of Europe Mesalamine Sales, by End User K Units (2015-2020)
  • Table 274. MEA Mesalamine Sales, by Country K Units (2015-2020)
  • Table 275. MEA Mesalamine Sales, by Type K Units (2015-2020)
  • Table 276. MEA Mesalamine Sales, by Application K Units (2015-2020)
  • Table 277. MEA Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 278. MEA Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 279. MEA Mesalamine Sales, by End User K Units (2015-2020)
  • Table 280. Middle East Mesalamine Sales, by Type K Units (2015-2020)
  • Table 281. Middle East Mesalamine Sales, by Application K Units (2015-2020)
  • Table 282. Middle East Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 283. Middle East Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 284. Middle East Mesalamine Sales, by End User K Units (2015-2020)
  • Table 285. Africa Mesalamine Sales, by Type K Units (2015-2020)
  • Table 286. Africa Mesalamine Sales, by Application K Units (2015-2020)
  • Table 287. Africa Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 288. Africa Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 289. Africa Mesalamine Sales, by End User K Units (2015-2020)
  • Table 290. North America Mesalamine Sales, by Country K Units (2015-2020)
  • Table 291. North America Mesalamine Sales, by Type K Units (2015-2020)
  • Table 292. North America Mesalamine Sales, by Application K Units (2015-2020)
  • Table 293. North America Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 294. North America Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 295. North America Mesalamine Sales, by End User K Units (2015-2020)
  • Table 296. United States Mesalamine Sales, by Type K Units (2015-2020)
  • Table 297. United States Mesalamine Sales, by Application K Units (2015-2020)
  • Table 298. United States Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 299. United States Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 300. United States Mesalamine Sales, by End User K Units (2015-2020)
  • Table 301. Canada Mesalamine Sales, by Type K Units (2015-2020)
  • Table 302. Canada Mesalamine Sales, by Application K Units (2015-2020)
  • Table 303. Canada Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 304. Canada Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 305. Canada Mesalamine Sales, by End User K Units (2015-2020)
  • Table 306. Mexico Mesalamine Sales, by Type K Units (2015-2020)
  • Table 307. Mexico Mesalamine Sales, by Application K Units (2015-2020)
  • Table 308. Mexico Mesalamine Sales, by Mode of Administration K Units (2015-2020)
  • Table 309. Mexico Mesalamine Sales, by Dosage K Units (2015-2020)
  • Table 310. Mexico Mesalamine Sales, by End User K Units (2015-2020)
  • Table 311. Mesalamine: by Type(USD/Units)
  • Table 312. Company Basic Information, Sales Area and Its Competitors
  • Table 313. Company Basic Information, Sales Area and Its Competitors
  • Table 314. Company Basic Information, Sales Area and Its Competitors
  • Table 315. Company Basic Information, Sales Area and Its Competitors
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Mesalamine: by Type(USD Million)
  • Table 323. Mesalamine Capsule , by Region USD Million (2021-2026)
  • Table 324. Mesalamine Tablets , by Region USD Million (2021-2026)
  • Table 325. Mesalamine Rectal Enema , by Region USD Million (2021-2026)
  • Table 326. Mesalamine: by Application(USD Million)
  • Table 327. Mesalamine Hospital , by Region USD Million (2021-2026)
  • Table 328. Mesalamine Pharmacies , by Region USD Million (2021-2026)
  • Table 329. Mesalamine Medical Stores , by Region USD Million (2021-2026)
  • Table 330. Mesalamine: by Mode of Administration(USD Million)
  • Table 331. Mesalamine Oral , by Region USD Million (2021-2026)
  • Table 332. Mesalamine Rectal , by Region USD Million (2021-2026)
  • Table 333. Mesalamine: by Dosage(USD Million)
  • Table 334. Mesalamine 250 mg , by Region USD Million (2021-2026)
  • Table 335. Mesalamine 375 mg , by Region USD Million (2021-2026)
  • Table 336. Mesalamine 400 mg , by Region USD Million (2021-2026)
  • Table 337. Mesalamine 500 mg , by Region USD Million (2021-2026)
  • Table 338. Mesalamine 800 mg , by Region USD Million (2021-2026)
  • Table 339. Mesalamine: by End User(USD Million)
  • Table 340. Mesalamine Adult , by Region USD Million (2021-2026)
  • Table 341. Mesalamine Children , by Region USD Million (2021-2026)
  • Table 342. South America Mesalamine, by Country USD Million (2021-2026)
  • Table 343. South America Mesalamine, by Type USD Million (2021-2026)
  • Table 344. South America Mesalamine, by Application USD Million (2021-2026)
  • Table 345. South America Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 346. South America Mesalamine, by Dosage USD Million (2021-2026)
  • Table 347. South America Mesalamine, by End User USD Million (2021-2026)
  • Table 348. Brazil Mesalamine, by Type USD Million (2021-2026)
  • Table 349. Brazil Mesalamine, by Application USD Million (2021-2026)
  • Table 350. Brazil Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 351. Brazil Mesalamine, by Dosage USD Million (2021-2026)
  • Table 352. Brazil Mesalamine, by End User USD Million (2021-2026)
  • Table 353. Argentina Mesalamine, by Type USD Million (2021-2026)
  • Table 354. Argentina Mesalamine, by Application USD Million (2021-2026)
  • Table 355. Argentina Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 356. Argentina Mesalamine, by Dosage USD Million (2021-2026)
  • Table 357. Argentina Mesalamine, by End User USD Million (2021-2026)
  • Table 358. Rest of South America Mesalamine, by Type USD Million (2021-2026)
  • Table 359. Rest of South America Mesalamine, by Application USD Million (2021-2026)
  • Table 360. Rest of South America Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 361. Rest of South America Mesalamine, by Dosage USD Million (2021-2026)
  • Table 362. Rest of South America Mesalamine, by End User USD Million (2021-2026)
  • Table 363. Asia Pacific Mesalamine, by Country USD Million (2021-2026)
  • Table 364. Asia Pacific Mesalamine, by Type USD Million (2021-2026)
  • Table 365. Asia Pacific Mesalamine, by Application USD Million (2021-2026)
  • Table 366. Asia Pacific Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 367. Asia Pacific Mesalamine, by Dosage USD Million (2021-2026)
  • Table 368. Asia Pacific Mesalamine, by End User USD Million (2021-2026)
  • Table 369. China Mesalamine, by Type USD Million (2021-2026)
  • Table 370. China Mesalamine, by Application USD Million (2021-2026)
  • Table 371. China Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 372. China Mesalamine, by Dosage USD Million (2021-2026)
  • Table 373. China Mesalamine, by End User USD Million (2021-2026)
  • Table 374. Japan Mesalamine, by Type USD Million (2021-2026)
  • Table 375. Japan Mesalamine, by Application USD Million (2021-2026)
  • Table 376. Japan Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 377. Japan Mesalamine, by Dosage USD Million (2021-2026)
  • Table 378. Japan Mesalamine, by End User USD Million (2021-2026)
  • Table 379. India Mesalamine, by Type USD Million (2021-2026)
  • Table 380. India Mesalamine, by Application USD Million (2021-2026)
  • Table 381. India Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 382. India Mesalamine, by Dosage USD Million (2021-2026)
  • Table 383. India Mesalamine, by End User USD Million (2021-2026)
  • Table 384. South Korea Mesalamine, by Type USD Million (2021-2026)
  • Table 385. South Korea Mesalamine, by Application USD Million (2021-2026)
  • Table 386. South Korea Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 387. South Korea Mesalamine, by Dosage USD Million (2021-2026)
  • Table 388. South Korea Mesalamine, by End User USD Million (2021-2026)
  • Table 389. Taiwan Mesalamine, by Type USD Million (2021-2026)
  • Table 390. Taiwan Mesalamine, by Application USD Million (2021-2026)
  • Table 391. Taiwan Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 392. Taiwan Mesalamine, by Dosage USD Million (2021-2026)
  • Table 393. Taiwan Mesalamine, by End User USD Million (2021-2026)
  • Table 394. Australia Mesalamine, by Type USD Million (2021-2026)
  • Table 395. Australia Mesalamine, by Application USD Million (2021-2026)
  • Table 396. Australia Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 397. Australia Mesalamine, by Dosage USD Million (2021-2026)
  • Table 398. Australia Mesalamine, by End User USD Million (2021-2026)
  • Table 399. Rest of Asia-Pacific Mesalamine, by Type USD Million (2021-2026)
  • Table 400. Rest of Asia-Pacific Mesalamine, by Application USD Million (2021-2026)
  • Table 401. Rest of Asia-Pacific Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 402. Rest of Asia-Pacific Mesalamine, by Dosage USD Million (2021-2026)
  • Table 403. Rest of Asia-Pacific Mesalamine, by End User USD Million (2021-2026)
  • Table 404. Europe Mesalamine, by Country USD Million (2021-2026)
  • Table 405. Europe Mesalamine, by Type USD Million (2021-2026)
  • Table 406. Europe Mesalamine, by Application USD Million (2021-2026)
  • Table 407. Europe Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 408. Europe Mesalamine, by Dosage USD Million (2021-2026)
  • Table 409. Europe Mesalamine, by End User USD Million (2021-2026)
  • Table 410. Germany Mesalamine, by Type USD Million (2021-2026)
  • Table 411. Germany Mesalamine, by Application USD Million (2021-2026)
  • Table 412. Germany Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 413. Germany Mesalamine, by Dosage USD Million (2021-2026)
  • Table 414. Germany Mesalamine, by End User USD Million (2021-2026)
  • Table 415. France Mesalamine, by Type USD Million (2021-2026)
  • Table 416. France Mesalamine, by Application USD Million (2021-2026)
  • Table 417. France Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 418. France Mesalamine, by Dosage USD Million (2021-2026)
  • Table 419. France Mesalamine, by End User USD Million (2021-2026)
  • Table 420. Italy Mesalamine, by Type USD Million (2021-2026)
  • Table 421. Italy Mesalamine, by Application USD Million (2021-2026)
  • Table 422. Italy Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 423. Italy Mesalamine, by Dosage USD Million (2021-2026)
  • Table 424. Italy Mesalamine, by End User USD Million (2021-2026)
  • Table 425. United Kingdom Mesalamine, by Type USD Million (2021-2026)
  • Table 426. United Kingdom Mesalamine, by Application USD Million (2021-2026)
  • Table 427. United Kingdom Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 428. United Kingdom Mesalamine, by Dosage USD Million (2021-2026)
  • Table 429. United Kingdom Mesalamine, by End User USD Million (2021-2026)
  • Table 430. Netherlands Mesalamine, by Type USD Million (2021-2026)
  • Table 431. Netherlands Mesalamine, by Application USD Million (2021-2026)
  • Table 432. Netherlands Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 433. Netherlands Mesalamine, by Dosage USD Million (2021-2026)
  • Table 434. Netherlands Mesalamine, by End User USD Million (2021-2026)
  • Table 435. Rest of Europe Mesalamine, by Type USD Million (2021-2026)
  • Table 436. Rest of Europe Mesalamine, by Application USD Million (2021-2026)
  • Table 437. Rest of Europe Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 438. Rest of Europe Mesalamine, by Dosage USD Million (2021-2026)
  • Table 439. Rest of Europe Mesalamine, by End User USD Million (2021-2026)
  • Table 440. MEA Mesalamine, by Country USD Million (2021-2026)
  • Table 441. MEA Mesalamine, by Type USD Million (2021-2026)
  • Table 442. MEA Mesalamine, by Application USD Million (2021-2026)
  • Table 443. MEA Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 444. MEA Mesalamine, by Dosage USD Million (2021-2026)
  • Table 445. MEA Mesalamine, by End User USD Million (2021-2026)
  • Table 446. Middle East Mesalamine, by Type USD Million (2021-2026)
  • Table 447. Middle East Mesalamine, by Application USD Million (2021-2026)
  • Table 448. Middle East Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 449. Middle East Mesalamine, by Dosage USD Million (2021-2026)
  • Table 450. Middle East Mesalamine, by End User USD Million (2021-2026)
  • Table 451. Africa Mesalamine, by Type USD Million (2021-2026)
  • Table 452. Africa Mesalamine, by Application USD Million (2021-2026)
  • Table 453. Africa Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 454. Africa Mesalamine, by Dosage USD Million (2021-2026)
  • Table 455. Africa Mesalamine, by End User USD Million (2021-2026)
  • Table 456. North America Mesalamine, by Country USD Million (2021-2026)
  • Table 457. North America Mesalamine, by Type USD Million (2021-2026)
  • Table 458. North America Mesalamine, by Application USD Million (2021-2026)
  • Table 459. North America Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 460. North America Mesalamine, by Dosage USD Million (2021-2026)
  • Table 461. North America Mesalamine, by End User USD Million (2021-2026)
  • Table 462. United States Mesalamine, by Type USD Million (2021-2026)
  • Table 463. United States Mesalamine, by Application USD Million (2021-2026)
  • Table 464. United States Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 465. United States Mesalamine, by Dosage USD Million (2021-2026)
  • Table 466. United States Mesalamine, by End User USD Million (2021-2026)
  • Table 467. Canada Mesalamine, by Type USD Million (2021-2026)
  • Table 468. Canada Mesalamine, by Application USD Million (2021-2026)
  • Table 469. Canada Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 470. Canada Mesalamine, by Dosage USD Million (2021-2026)
  • Table 471. Canada Mesalamine, by End User USD Million (2021-2026)
  • Table 472. Mexico Mesalamine, by Type USD Million (2021-2026)
  • Table 473. Mexico Mesalamine, by Application USD Million (2021-2026)
  • Table 474. Mexico Mesalamine, by Mode of Administration USD Million (2021-2026)
  • Table 475. Mexico Mesalamine, by Dosage USD Million (2021-2026)
  • Table 476. Mexico Mesalamine, by End User USD Million (2021-2026)
  • Table 477. Mesalamine Sales: by Type(K Units)
  • Table 478. Mesalamine Sales Capsule , by Region K Units (2021-2026)
  • Table 479. Mesalamine Sales Tablets , by Region K Units (2021-2026)
  • Table 480. Mesalamine Sales Rectal Enema , by Region K Units (2021-2026)
  • Table 481. Mesalamine Sales: by Application(K Units)
  • Table 482. Mesalamine Sales Hospital , by Region K Units (2021-2026)
  • Table 483. Mesalamine Sales Pharmacies , by Region K Units (2021-2026)
  • Table 484. Mesalamine Sales Medical Stores , by Region K Units (2021-2026)
  • Table 485. Mesalamine Sales: by Mode of Administration(K Units)
  • Table 486. Mesalamine Sales Oral , by Region K Units (2021-2026)
  • Table 487. Mesalamine Sales Rectal , by Region K Units (2021-2026)
  • Table 488. Mesalamine Sales: by Dosage(K Units)
  • Table 489. Mesalamine Sales 250 mg , by Region K Units (2021-2026)
  • Table 490. Mesalamine Sales 375 mg , by Region K Units (2021-2026)
  • Table 491. Mesalamine Sales 400 mg , by Region K Units (2021-2026)
  • Table 492. Mesalamine Sales 500 mg , by Region K Units (2021-2026)
  • Table 493. Mesalamine Sales 800 mg , by Region K Units (2021-2026)
  • Table 494. Mesalamine Sales: by End User(K Units)
  • Table 495. Mesalamine Sales Adult , by Region K Units (2021-2026)
  • Table 496. Mesalamine Sales Children , by Region K Units (2021-2026)
  • Table 497. South America Mesalamine Sales, by Country K Units (2021-2026)
  • Table 498. South America Mesalamine Sales, by Type K Units (2021-2026)
  • Table 499. South America Mesalamine Sales, by Application K Units (2021-2026)
  • Table 500. South America Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 501. South America Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 502. South America Mesalamine Sales, by End User K Units (2021-2026)
  • Table 503. Brazil Mesalamine Sales, by Type K Units (2021-2026)
  • Table 504. Brazil Mesalamine Sales, by Application K Units (2021-2026)
  • Table 505. Brazil Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 506. Brazil Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 507. Brazil Mesalamine Sales, by End User K Units (2021-2026)
  • Table 508. Argentina Mesalamine Sales, by Type K Units (2021-2026)
  • Table 509. Argentina Mesalamine Sales, by Application K Units (2021-2026)
  • Table 510. Argentina Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 511. Argentina Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 512. Argentina Mesalamine Sales, by End User K Units (2021-2026)
  • Table 513. Rest of South America Mesalamine Sales, by Type K Units (2021-2026)
  • Table 514. Rest of South America Mesalamine Sales, by Application K Units (2021-2026)
  • Table 515. Rest of South America Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 516. Rest of South America Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 517. Rest of South America Mesalamine Sales, by End User K Units (2021-2026)
  • Table 518. Asia Pacific Mesalamine Sales, by Country K Units (2021-2026)
  • Table 519. Asia Pacific Mesalamine Sales, by Type K Units (2021-2026)
  • Table 520. Asia Pacific Mesalamine Sales, by Application K Units (2021-2026)
  • Table 521. Asia Pacific Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 522. Asia Pacific Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 523. Asia Pacific Mesalamine Sales, by End User K Units (2021-2026)
  • Table 524. China Mesalamine Sales, by Type K Units (2021-2026)
  • Table 525. China Mesalamine Sales, by Application K Units (2021-2026)
  • Table 526. China Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 527. China Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 528. China Mesalamine Sales, by End User K Units (2021-2026)
  • Table 529. Japan Mesalamine Sales, by Type K Units (2021-2026)
  • Table 530. Japan Mesalamine Sales, by Application K Units (2021-2026)
  • Table 531. Japan Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 532. Japan Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 533. Japan Mesalamine Sales, by End User K Units (2021-2026)
  • Table 534. India Mesalamine Sales, by Type K Units (2021-2026)
  • Table 535. India Mesalamine Sales, by Application K Units (2021-2026)
  • Table 536. India Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 537. India Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 538. India Mesalamine Sales, by End User K Units (2021-2026)
  • Table 539. South Korea Mesalamine Sales, by Type K Units (2021-2026)
  • Table 540. South Korea Mesalamine Sales, by Application K Units (2021-2026)
  • Table 541. South Korea Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 542. South Korea Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 543. South Korea Mesalamine Sales, by End User K Units (2021-2026)
  • Table 544. Taiwan Mesalamine Sales, by Type K Units (2021-2026)
  • Table 545. Taiwan Mesalamine Sales, by Application K Units (2021-2026)
  • Table 546. Taiwan Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 547. Taiwan Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 548. Taiwan Mesalamine Sales, by End User K Units (2021-2026)
  • Table 549. Australia Mesalamine Sales, by Type K Units (2021-2026)
  • Table 550. Australia Mesalamine Sales, by Application K Units (2021-2026)
  • Table 551. Australia Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 552. Australia Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 553. Australia Mesalamine Sales, by End User K Units (2021-2026)
  • Table 554. Rest of Asia-Pacific Mesalamine Sales, by Type K Units (2021-2026)
  • Table 555. Rest of Asia-Pacific Mesalamine Sales, by Application K Units (2021-2026)
  • Table 556. Rest of Asia-Pacific Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 557. Rest of Asia-Pacific Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 558. Rest of Asia-Pacific Mesalamine Sales, by End User K Units (2021-2026)
  • Table 559. Europe Mesalamine Sales, by Country K Units (2021-2026)
  • Table 560. Europe Mesalamine Sales, by Type K Units (2021-2026)
  • Table 561. Europe Mesalamine Sales, by Application K Units (2021-2026)
  • Table 562. Europe Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 563. Europe Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 564. Europe Mesalamine Sales, by End User K Units (2021-2026)
  • Table 565. Germany Mesalamine Sales, by Type K Units (2021-2026)
  • Table 566. Germany Mesalamine Sales, by Application K Units (2021-2026)
  • Table 567. Germany Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 568. Germany Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 569. Germany Mesalamine Sales, by End User K Units (2021-2026)
  • Table 570. France Mesalamine Sales, by Type K Units (2021-2026)
  • Table 571. France Mesalamine Sales, by Application K Units (2021-2026)
  • Table 572. France Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 573. France Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 574. France Mesalamine Sales, by End User K Units (2021-2026)
  • Table 575. Italy Mesalamine Sales, by Type K Units (2021-2026)
  • Table 576. Italy Mesalamine Sales, by Application K Units (2021-2026)
  • Table 577. Italy Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 578. Italy Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 579. Italy Mesalamine Sales, by End User K Units (2021-2026)
  • Table 580. United Kingdom Mesalamine Sales, by Type K Units (2021-2026)
  • Table 581. United Kingdom Mesalamine Sales, by Application K Units (2021-2026)
  • Table 582. United Kingdom Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 583. United Kingdom Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 584. United Kingdom Mesalamine Sales, by End User K Units (2021-2026)
  • Table 585. Netherlands Mesalamine Sales, by Type K Units (2021-2026)
  • Table 586. Netherlands Mesalamine Sales, by Application K Units (2021-2026)
  • Table 587. Netherlands Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 588. Netherlands Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 589. Netherlands Mesalamine Sales, by End User K Units (2021-2026)
  • Table 590. Rest of Europe Mesalamine Sales, by Type K Units (2021-2026)
  • Table 591. Rest of Europe Mesalamine Sales, by Application K Units (2021-2026)
  • Table 592. Rest of Europe Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 593. Rest of Europe Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 594. Rest of Europe Mesalamine Sales, by End User K Units (2021-2026)
  • Table 595. MEA Mesalamine Sales, by Country K Units (2021-2026)
  • Table 596. MEA Mesalamine Sales, by Type K Units (2021-2026)
  • Table 597. MEA Mesalamine Sales, by Application K Units (2021-2026)
  • Table 598. MEA Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 599. MEA Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 600. MEA Mesalamine Sales, by End User K Units (2021-2026)
  • Table 601. Middle East Mesalamine Sales, by Type K Units (2021-2026)
  • Table 602. Middle East Mesalamine Sales, by Application K Units (2021-2026)
  • Table 603. Middle East Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 604. Middle East Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 605. Middle East Mesalamine Sales, by End User K Units (2021-2026)
  • Table 606. Africa Mesalamine Sales, by Type K Units (2021-2026)
  • Table 607. Africa Mesalamine Sales, by Application K Units (2021-2026)
  • Table 608. Africa Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 609. Africa Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 610. Africa Mesalamine Sales, by End User K Units (2021-2026)
  • Table 611. North America Mesalamine Sales, by Country K Units (2021-2026)
  • Table 612. North America Mesalamine Sales, by Type K Units (2021-2026)
  • Table 613. North America Mesalamine Sales, by Application K Units (2021-2026)
  • Table 614. North America Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 615. North America Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 616. North America Mesalamine Sales, by End User K Units (2021-2026)
  • Table 617. United States Mesalamine Sales, by Type K Units (2021-2026)
  • Table 618. United States Mesalamine Sales, by Application K Units (2021-2026)
  • Table 619. United States Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 620. United States Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 621. United States Mesalamine Sales, by End User K Units (2021-2026)
  • Table 622. Canada Mesalamine Sales, by Type K Units (2021-2026)
  • Table 623. Canada Mesalamine Sales, by Application K Units (2021-2026)
  • Table 624. Canada Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 625. Canada Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 626. Canada Mesalamine Sales, by End User K Units (2021-2026)
  • Table 627. Mexico Mesalamine Sales, by Type K Units (2021-2026)
  • Table 628. Mexico Mesalamine Sales, by Application K Units (2021-2026)
  • Table 629. Mexico Mesalamine Sales, by Mode of Administration K Units (2021-2026)
  • Table 630. Mexico Mesalamine Sales, by Dosage K Units (2021-2026)
  • Table 631. Mexico Mesalamine Sales, by End User K Units (2021-2026)
  • Table 632. Mesalamine: by Type(USD/Units)
  • Table 633. Research Programs/Design for This Report
  • Table 634. Key Data Information from Secondary Sources
  • Table 635. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mesalamine: by Type USD Million (2015-2020)
  • Figure 5. Global Mesalamine: by Application USD Million (2015-2020)
  • Figure 6. Global Mesalamine: by Mode of Administration USD Million (2015-2020)
  • Figure 7. Global Mesalamine: by Dosage USD Million (2015-2020)
  • Figure 8. Global Mesalamine: by End User USD Million (2015-2020)
  • Figure 9. South America Mesalamine Share (%), by Country
  • Figure 10. Asia Pacific Mesalamine Share (%), by Country
  • Figure 11. Europe Mesalamine Share (%), by Country
  • Figure 12. MEA Mesalamine Share (%), by Country
  • Figure 13. North America Mesalamine Share (%), by Country
  • Figure 14. Global Mesalamine: by Type K Units (2015-2020)
  • Figure 15. Global Mesalamine: by Application K Units (2015-2020)
  • Figure 16. Global Mesalamine: by Mode of Administration K Units (2015-2020)
  • Figure 17. Global Mesalamine: by Dosage K Units (2015-2020)
  • Figure 18. Global Mesalamine: by End User K Units (2015-2020)
  • Figure 19. South America Mesalamine Share (%), by Country
  • Figure 20. Asia Pacific Mesalamine Share (%), by Country
  • Figure 21. Europe Mesalamine Share (%), by Country
  • Figure 22. MEA Mesalamine Share (%), by Country
  • Figure 23. North America Mesalamine Share (%), by Country
  • Figure 24. Global Mesalamine: by Type USD/Units (2015-2020)
  • Figure 25. Global Mesalamine share by Players 2020 (%)
  • Figure 26. Global Mesalamine share by Players (Top 3) 2020(%)
  • Figure 27. Global Mesalamine share by Players (Top 5) 2020(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Salix Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Salix Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Nogra Pharma Limited (Ireland) Revenue, Net Income and Gross profit
  • Figure 32. Nogra Pharma Limited (Ireland) Revenue: by Geography 2020
  • Figure 33. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 35. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 36. AbbVie (United States) Revenue: by Geography 2020
  • Figure 37. The Takeda Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 38. The Takeda Pharmaceutical (Japan) Revenue: by Geography 2020
  • Figure 39. Janssen Pharmaceutica (Belgium) Revenue, Net Income and Gross profit
  • Figure 40. Janssen Pharmaceutica (Belgium) Revenue: by Geography 2020
  • Figure 41. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 43. Ferring Holding SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. Ferring Holding SA (Switzerland) Revenue: by Geography 2020
  • Figure 45. C.H. Boehringer Sohn AG & Ko. (Germany) Revenue, Net Income and Gross profit
  • Figure 46. C.H. Boehringer Sohn AG & Ko. (Germany) Revenue: by Geography 2020
  • Figure 47. Cosmo Pharmaceuticals (Ireland) Revenue, Net Income and Gross profit
  • Figure 48. Cosmo Pharmaceuticals (Ireland) Revenue: by Geography 2020
  • Figure 49. Global Mesalamine: by Type USD Million (2021-2026)
  • Figure 50. Global Mesalamine: by Application USD Million (2021-2026)
  • Figure 51. Global Mesalamine: by Mode of Administration USD Million (2021-2026)
  • Figure 52. Global Mesalamine: by Dosage USD Million (2021-2026)
  • Figure 53. Global Mesalamine: by End User USD Million (2021-2026)
  • Figure 54. South America Mesalamine Share (%), by Country
  • Figure 55. Asia Pacific Mesalamine Share (%), by Country
  • Figure 56. Europe Mesalamine Share (%), by Country
  • Figure 57. MEA Mesalamine Share (%), by Country
  • Figure 58. North America Mesalamine Share (%), by Country
  • Figure 59. Global Mesalamine: by Type K Units (2021-2026)
  • Figure 60. Global Mesalamine: by Application K Units (2021-2026)
  • Figure 61. Global Mesalamine: by Mode of Administration K Units (2021-2026)
  • Figure 62. Global Mesalamine: by Dosage K Units (2021-2026)
  • Figure 63. Global Mesalamine: by End User K Units (2021-2026)
  • Figure 64. South America Mesalamine Share (%), by Country
  • Figure 65. Asia Pacific Mesalamine Share (%), by Country
  • Figure 66. Europe Mesalamine Share (%), by Country
  • Figure 67. MEA Mesalamine Share (%), by Country
  • Figure 68. North America Mesalamine Share (%), by Country
  • Figure 69. Global Mesalamine: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Salix Pharmaceuticals, Inc. (United States)
  • Nogra Pharma Limited (Ireland)
  • AstraZeneca plc (United Kingdom)
  • AbbVie (United States)
  • The Takeda Pharmaceutical (Japan)
  • Janssen Pharmaceutica (Belgium)
  • Pfizer Inc. (United States)
  • Ferring Holding SA (Switzerland)
  • C.H. Boehringer Sohn AG & Ko. (Germany)
  • Cosmo Pharmaceuticals (Ireland)
Additional players considered in the study are as follows:
Teva Pharmaceutical Industries Ltd.(Israel) , Mylan N.V. (United States)
Select User Access Type

Key Highlights of Report


Aug 2021 211 Pages 79 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Mesalamine Market Quantitative research analysis
Global Mesalamine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Mesalamine market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Mesalamine market are Salix Pharmaceuticals, Inc. (United States), Nogra Pharma Limited (Ireland), AstraZeneca plc (United Kingdom), AbbVie (United States), The Takeda Pharmaceutical (Japan), Janssen Pharmaceutica (Belgium), Pfizer Inc. (United States), Ferring Holding SA (Switzerland), C.H. Boehringer Sohn AG & Ko. (Germany) and Cosmo Pharmaceuticals (Ireland), to name a few.
In this highly competitive & fast evolving Mesalamine industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Mesalamine Market Report?

Have a Query? Click Here

Other Related Reports

Iron Sucrose Injection Comprehensive Study by Application (Adult, Adolescents, Geriatric, Children), Distribution Channels (Online Pharmacy, Medical Stores, Hospital Pharmacy, Others), End User (Hosp...
$ 3650
Phosphate Binder Comprehensive Study by Type (Calcium Carbonate, Calcium Acetate, Sevelamer Hydrochloride, Lanthanum Carbonate, Magnesium Hydroxide, Sucroferric Oxyhydroxide, Ferric Citrate, Others),...
$ 3650
Milk Thistle Supplement Comprehensive Study by Application (Food Industry, Cosmetic Industry, Pharmaceutical Industry), Form (Capsules, Tablets, Soft gel), Distribution Channel (Hypermarket/Supermark...
$ 3650
Cancer Hormone Therapy Drugs Comprehensive Study by Application (Treat Prostate Cancer, Breast Cancers, Endometrial Cancer, Uterine Cancer, Other Cancer Treatments), Drug (Anti-Estrogen Drugs, Aromat...
$ 3750
Vitamin D Therapy Comprehensive Study by Type (Vitamin D3, Vitamin D2), Application (Pharmaceuticals, Functional Food & Beverages, Personal Care, Feed & Pet Food, Animal Feed, Pet Food, Supplements a...
$ 3750
Microneedle Drug Delivery Systems  Comprehensive Study by Type (Hollow Microneedle Technology, Solid Microneedle Technology, Dissolving Microneedles Technology), Application (Drug Delivery, Vaccine D...
$ 3750